Pd-1 blockade in a liver transplant recipient with microsatellite unstable metastatic colorectal cancer and hepatic impairment

Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold, May T. Cho

Research output: Contribution to journalArticle

Abstract

Immune checkpoint inhibitors represent a newly established standard of care in patients with refractory metastatic colorectal cancer with mismatch repair deficiency and microsatellite instability. However, the use of immunotherapy is unclear in recipients of liver transplants with or without concurrent liver function abnormalities. Clinical trials investigating immunotherapy have mostly excluded liver transplant recipients and patients with abnormal liver function. This report presents the first case, to our knowledge, of a liver transplant patient with mismatch repair-deficient colon adenocarcinoma with liver metastases and concurrent abnormal liver function who safely responded to immunotherapy. We also review the literature on checkpoint inhibitor use in patients with other metastatic solid tumors after liver transplant and those with baseline liver function abnormalities. An increasing body of evidence supports the safety of checkpoint inhibition in patients with cancer and solid organ transplants, but further prospective studies are warranted. Use of immunotherapy in liver transplant recipients who have metastatic colorectal cancer with microsatellite instability is feasible but should be performed in a multidisciplinary team setting.

Original languageEnglish (US)
Pages (from-to)1026-1030
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Microsatellite Repeats
Colorectal Neoplasms
Liver
Immunotherapy
Microsatellite Instability
Transplants
Transplant Recipients
DNA Mismatch Repair
Standard of Care
Neoplasms
Colon
Adenocarcinoma
Clinical Trials
Prospective Studies
Neoplasm Metastasis
Safety

ASJC Scopus subject areas

  • Oncology

Cite this

Pd-1 blockade in a liver transplant recipient with microsatellite unstable metastatic colorectal cancer and hepatic impairment. / Chen, Justin A.; Esteghamat, Naseem; Kim, Edward J.; Garcia, Gabriel; Gong, Jun; Fakih, Marwan G.; Bold, Richard J.; Cho, May T.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 17, No. 9, 01.01.2019, p. 1026-1030.

Research output: Contribution to journalArticle

@article{2610df95a869480f9cd30e62d34627a2,
title = "Pd-1 blockade in a liver transplant recipient with microsatellite unstable metastatic colorectal cancer and hepatic impairment",
abstract = "Immune checkpoint inhibitors represent a newly established standard of care in patients with refractory metastatic colorectal cancer with mismatch repair deficiency and microsatellite instability. However, the use of immunotherapy is unclear in recipients of liver transplants with or without concurrent liver function abnormalities. Clinical trials investigating immunotherapy have mostly excluded liver transplant recipients and patients with abnormal liver function. This report presents the first case, to our knowledge, of a liver transplant patient with mismatch repair-deficient colon adenocarcinoma with liver metastases and concurrent abnormal liver function who safely responded to immunotherapy. We also review the literature on checkpoint inhibitor use in patients with other metastatic solid tumors after liver transplant and those with baseline liver function abnormalities. An increasing body of evidence supports the safety of checkpoint inhibition in patients with cancer and solid organ transplants, but further prospective studies are warranted. Use of immunotherapy in liver transplant recipients who have metastatic colorectal cancer with microsatellite instability is feasible but should be performed in a multidisciplinary team setting.",
author = "Chen, {Justin A.} and Naseem Esteghamat and Kim, {Edward J.} and Gabriel Garcia and Jun Gong and Fakih, {Marwan G.} and Bold, {Richard J.} and Cho, {May T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.6004/jnccn.2019.7328",
language = "English (US)",
volume = "17",
pages = "1026--1030",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Pd-1 blockade in a liver transplant recipient with microsatellite unstable metastatic colorectal cancer and hepatic impairment

AU - Chen, Justin A.

AU - Esteghamat, Naseem

AU - Kim, Edward J.

AU - Garcia, Gabriel

AU - Gong, Jun

AU - Fakih, Marwan G.

AU - Bold, Richard J.

AU - Cho, May T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Immune checkpoint inhibitors represent a newly established standard of care in patients with refractory metastatic colorectal cancer with mismatch repair deficiency and microsatellite instability. However, the use of immunotherapy is unclear in recipients of liver transplants with or without concurrent liver function abnormalities. Clinical trials investigating immunotherapy have mostly excluded liver transplant recipients and patients with abnormal liver function. This report presents the first case, to our knowledge, of a liver transplant patient with mismatch repair-deficient colon adenocarcinoma with liver metastases and concurrent abnormal liver function who safely responded to immunotherapy. We also review the literature on checkpoint inhibitor use in patients with other metastatic solid tumors after liver transplant and those with baseline liver function abnormalities. An increasing body of evidence supports the safety of checkpoint inhibition in patients with cancer and solid organ transplants, but further prospective studies are warranted. Use of immunotherapy in liver transplant recipients who have metastatic colorectal cancer with microsatellite instability is feasible but should be performed in a multidisciplinary team setting.

AB - Immune checkpoint inhibitors represent a newly established standard of care in patients with refractory metastatic colorectal cancer with mismatch repair deficiency and microsatellite instability. However, the use of immunotherapy is unclear in recipients of liver transplants with or without concurrent liver function abnormalities. Clinical trials investigating immunotherapy have mostly excluded liver transplant recipients and patients with abnormal liver function. This report presents the first case, to our knowledge, of a liver transplant patient with mismatch repair-deficient colon adenocarcinoma with liver metastases and concurrent abnormal liver function who safely responded to immunotherapy. We also review the literature on checkpoint inhibitor use in patients with other metastatic solid tumors after liver transplant and those with baseline liver function abnormalities. An increasing body of evidence supports the safety of checkpoint inhibition in patients with cancer and solid organ transplants, but further prospective studies are warranted. Use of immunotherapy in liver transplant recipients who have metastatic colorectal cancer with microsatellite instability is feasible but should be performed in a multidisciplinary team setting.

UR - http://www.scopus.com/inward/record.url?scp=85071749995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071749995&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.7328

DO - 10.6004/jnccn.2019.7328

M3 - Article

C2 - 31487676

AN - SCOPUS:85071749995

VL - 17

SP - 1026

EP - 1030

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 9

ER -